Sleek Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 23-10-2024
- Paid Up Capital ₹ 0.51 M
as on 23-10-2024
- Company Age 27 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.00 M
as on 23-10-2024
- Revenue 2.23%
(FY 2023)
- Profit 4.08%
(FY 2023)
- Ebitda 29.40%
(FY 2023)
- Net Worth 6.04%
(FY 2023)
- Total Assets 5.10%
(FY 2023)
About Sleek Pharmaceuticals
The Company is engaged in the Infrastructure And Utilities Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.51 M.
The company currently has active open charges totaling ₹6.00 M.
Jai Deep, Adip Kumar, and Ravinder Kumar serve as directors at the Company.
- CIN/LLPIN
U24232DL1997PTC088270
- Company No.
088270
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Jul 1997
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sleek Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Jai Deep  | Director | 01-Jul-1997 | Current |
| Adip Kumar | Director | 01-Jul-1997 | Current |
| Ravinder Kumar | Director | 01-Jul-1997 | Current |
Financial Performance of Sleek Pharmaceuticals.
Sleek Pharmaceuticals Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.23% increase. The company also saw a slight improvement in profitability, with a 4.08% increase in profit. The company's net worth moved up by a moderate rise of 6.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sleek Pharmaceuticals?
In 2023, Sleek Pharmaceuticals had a promoter holding of 36.41% and a public holding of 63.59%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Shivalik Medicare Private LimitedActive 37 years 9 daysJai Deep, Adip Kumar and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Pnb Housing Finance Limited Creation Date: 06 May 2008 | ₹6.00 M | Open |
How Many Employees Work at Sleek Pharmaceuticals?
Sleek Pharmaceuticals has a workforce of 4 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sleek Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sleek Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
